Creative Medical Technology Holdings, Inc. Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature
Creative Medical Technology Holdings, Inc. (CELZ) reported Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature of $0 for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-30.
Discontinued › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature · last filed 2022-03-30
- Creative Medical Technology Holdings, Inc. adjustments to additional paid in capital, convertible debt with conversion feature for fiscal 2021 was $0.00, a 100.00% decline from fiscal 2020.
- Creative Medical Technology Holdings, Inc. adjustments to additional paid in capital, convertible debt with conversion feature for fiscal 2020 was $101.35K.
- Creative Medical Technology Holdings, Inc. adjustments to additional paid in capital, convertible debt with conversion feature for fiscal 2019 was $0.00.
| Period end | Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature 12 month |
|---|---|
| 2021-12-31 | $0.00 10-K · filed 2022-03-30 |
| 2020-12-31 | $101.35K 10-K · filed 2022-03-30 |
| 2019-12-31 | $0.00 10-K · filed 2021-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| Calidi Biotherapeutics, Inc. (CLDI) | United States | $0.003B | |
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| Silexion Therapeutics Corp (SLXN) | $0.001B |